EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting ARF6-SUCNR1 Axis: Antisense Oligonucleotide Adjuvants for Neutrophil Immunometabolism

Yangyang Wang iD, Ye Chen

International Journal of Molecular Sciences · 04.08.2026 · 27 (15) · 7007

DOI: 10.3390/ijms27157007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.08.2026. Verfasst von Yangyang Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Jilin Collaborative Innovation Center for Antibody Engineering, Jilin Medical University, Jilin 132013, China. Hauptthemen laut MEDLINE: ADP-Ribosylation Factors, Neutrophils, Oligonucleotides, Antisense, Receptors, G-Protein-Coupled. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Province Science and Technology Department, Jilin Medical University, Health Science and Technology Capability Enhancement Project of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional vaccine adjuvants often lack cell-type specificity and readily trigger excessive systemic inflammation, limiting their clinical application. Immunometabolic signaling centered on the ARF6 (ADP-ribosylation factor 6)-SUCNR1 (Succinate receptor 1) axis governs neutrophil recruitment and subsequent B-cell activation at vaccination sites, offering a promising target to balance adjuvant potency and biosafety. Separately published single-gene data confirm two opposing functions for the two mediators: ARF6 overactivation amplifies local pathological inflammation, whereas succinate-stimulated SUCNR1 drives neutrophil infiltration and humoral immune priming. However, direct paired evidence verifying their bidirectional crosstalk within immunization microenvironments remains limited. This review systematically integrates current research on ARF6 and SUCNR1 immunometabolism to outline a hypothetical dual-regulatory adjuvant strategy: local, transient partial silencing of pathological ARF6 activity via ARF6-targeted ASOs (antisense oligonucleotides) paired with localized succinate delivery to sustain protective SUCNR1 signaling. We summarize the molecular basis of this “one inhibition, one activation” paradigm, alongside ASO chemical modification, myeloid-targeted design, and nanocarrier delivery solutions that resolve the unique ARF6 endocytosis paradox. We further dissect unresolved translational risks, including concentration-dependent succinate inflammatory effects, carrier immunogenicity, and potential impairment of baseline neutrophil migration upon ARF6 suppression. Overall, this work synthesizes fragmented mechanistic data to construct a testable neutrophil-centered adjuvant framework, and highlights outstanding technical and biosafety hurdles that require dedicated preclinical validation to support future adjuvant development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADP-Ribosylation FactorsNeutrophilsOligonucleotides, AntisenseReceptors, G-Protein-CoupledAdjuvants, ImmunologicADP-Ribosylation Factor 6HumansAnimalsSignal TransductionNeutrophil InfiltrationDuffy Blood-Group SystemReceptors, Cell Surface

Stichwörter der Autor:innen

ARF6ASOSUCNR1immune responseimmunometabolisminflammationneutrophilvaccine adjuvant

Substanzen

ADP-Ribosylation FactorsADP-Ribosylation Factor 6ARF6 protein, humanOligonucleotides, AntisenseReceptors, G-Protein-CoupledAdjuvants, ImmunologicACKR1 protein, humanDuffy Blood-Group SystemReceptors, Cell Surface

Autor:innen und Institutionen

  • Jilin Collaborative Innovation Center for Antibody Engineering, Jilin Medical University, Jilin 132013, China.

ORCID-Profile: Yangyang Wang

Förderung

  • Jilin Province Science and Technology Department
  • Jilin Medical University
  • Health Science and Technology Capability Enhancement Project of Jilin Province
  • Natural Science Foundation of Jilin Province
  • Doctoral Research Initiation Funding, Jilin Medical University

Zitieren

APA

Wang, Y., & Chen, Y. (2026). Targeting ARF6-SUCNR1 Axis: Antisense Oligonucleotide Adjuvants for Neutrophil Immunometabolism. International Journal of Molecular Sciences, 27(15), 7007. https://doi.org/10.3390/ijms27157007

Vancouver

Wang Y, Chen Y. Targeting ARF6-SUCNR1 Axis: Antisense Oligonucleotide Adjuvants for Neutrophil Immunometabolism. International Journal of Molecular Sciences. 2026;27(15):7007. doi:10.3390/ijms27157007

BibTeX
@article{Wang2026,
  author = {Wang, Yangyang and Chen, Ye},
  title = {Targeting ARF6-SUCNR1 Axis: Antisense Oligonucleotide Adjuvants for Neutrophil Immunometabolism},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {7007},
  doi = {10.3390/ijms27157007}
}
Kostenlos starten →